Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction

R. A. Nathan, J. A. Bernstein, L. Bielory, C. M. Bonuccelli, William Calhoun, S. P. Galant, L. A. Hanby, J. P. Kemp, J. W. Kylstra, A. S. Nayak, J. P. O'Connor, H. J. Schwartz, D. L. Southern, S. L. Spector, P. V. Williams, D. W. Aaronson, R. V. Albery, D. Auerbach, T. D. Bell, W. E. Berger & 31 others C. A. Bruce, J. H. Butterfield, S. C. Campbell, S. Chodosh, T. J. Chu, M. Cohen, J. A. Colton, A. C. DeGraff, R. J. Dockhorn, T. B. Edwards, A. Floreani, S. A. Gillman, S. Goldstein, F. Hampel, P. J. Hannaway, S. R. Hirsch, L. Kirby, D. M. Lang, T. W. Littlejohn, D. Q. Mitchell, T. Montanaro, Z. M. Munk, S. Pollard, P. H. Ratner, L. J. Rossoff, M. S. Rowe, M. Schatz, J. R. Taylor, R. G. Townley, L. A. Weiss, S. Weiss

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma. Objectives: We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) during a 13- week, double-blind, placebo-controlled, multicenter trial in adults and adolescents with moderate reversible airflow obstruction. Methods: Patients (age range, 12 to 68 years) with total daytime asthma symptoms scores of 10 or greater over 7 consecutive days (maximum, 21/wk), FEV1 45% or greater but less than or equal to 80% of predicted value (≥6 hours after β2-agonist), and reversible airway disease were randomized to 20 mg zafirlukast twice daily (n(Z) = 231) or placebo twice daily (n(P) = 223). Efficacy was assessed from changes in daytime and nocturnal symptoms, β2-agonist use, nasal congestion score, and pulmonary function. QOL was evaluated with a disease- specific Asthma Quality of Life Questionnaire. Safety was determined from adverse event information and clinical laboratory test results. Results: Zafirlukast was significantly (P < .001) more effective than placebo, with reductions from baseline in the daytime asthma symptoms score (-23%), nighttime awakenings with asthma (-19%), and β2-agonist use (-24%) and improvements from baseline in morning (+25 L/min) and evening (+18 L/min) peak expiratory flow rates. Compared with placebo, zafirlukast significantly (P ≤ .018) improved scores for QOL domains (activity limitations, symptoms, emotional function, and exposure to environmental stimuli) and overall QOL, with a significantly greater proportion of zafirlukast-treated patients demonstrating clinically meaningful improvements (≥0.5-unit change from baseline; P ≤ .037). The safety profile of zafirlukast was clinically indistinguishable from that of placebo. Conclusions: Zafirlukast is effective and well tolerated and improves QOL in the long-term treatment of patients with moderate reversible airflow obstruction.

Original languageEnglish (US)
Pages (from-to)935-942
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume102
Issue number6 I
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Asthma
Quality of Life
Placebos
Safety
Leukotriene Antagonists
Peak Expiratory Flow Rate
zafirlukast
Environmental Exposure
Nose
Multicenter Studies
Lung

Keywords

  • Asthma
  • Leukotriene receptor antagonist
  • Nasal congestion
  • Number needed to treat
  • Peripheral blood eosinophils
  • Pulmonary function
  • Quality of life
  • Reversible airflow obstruction
  • Zafirlukast

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. / Nathan, R. A.; Bernstein, J. A.; Bielory, L.; Bonuccelli, C. M.; Calhoun, William; Galant, S. P.; Hanby, L. A.; Kemp, J. P.; Kylstra, J. W.; Nayak, A. S.; O'Connor, J. P.; Schwartz, H. J.; Southern, D. L.; Spector, S. L.; Williams, P. V.; Aaronson, D. W.; Albery, R. V.; Auerbach, D.; Bell, T. D.; Berger, W. E.; Bruce, C. A.; Butterfield, J. H.; Campbell, S. C.; Chodosh, S.; Chu, T. J.; Cohen, M.; Colton, J. A.; DeGraff, A. C.; Dockhorn, R. J.; Edwards, T. B.; Floreani, A.; Gillman, S. A.; Goldstein, S.; Hampel, F.; Hannaway, P. J.; Hirsch, S. R.; Kirby, L.; Lang, D. M.; Littlejohn, T. W.; Mitchell, D. Q.; Montanaro, T.; Munk, Z. M.; Pollard, S.; Ratner, P. H.; Rossoff, L. J.; Rowe, M. S.; Schatz, M.; Taylor, J. R.; Townley, R. G.; Weiss, L. A.; Weiss, S.

In: Journal of Allergy and Clinical Immunology, Vol. 102, No. 6 I, 1998, p. 935-942.

Research output: Contribution to journalArticle

Nathan, RA, Bernstein, JA, Bielory, L, Bonuccelli, CM, Calhoun, W, Galant, SP, Hanby, LA, Kemp, JP, Kylstra, JW, Nayak, AS, O'Connor, JP, Schwartz, HJ, Southern, DL, Spector, SL, Williams, PV, Aaronson, DW, Albery, RV, Auerbach, D, Bell, TD, Berger, WE, Bruce, CA, Butterfield, JH, Campbell, SC, Chodosh, S, Chu, TJ, Cohen, M, Colton, JA, DeGraff, AC, Dockhorn, RJ, Edwards, TB, Floreani, A, Gillman, SA, Goldstein, S, Hampel, F, Hannaway, PJ, Hirsch, SR, Kirby, L, Lang, DM, Littlejohn, TW, Mitchell, DQ, Montanaro, T, Munk, ZM, Pollard, S, Ratner, PH, Rossoff, LJ, Rowe, MS, Schatz, M, Taylor, JR, Townley, RG, Weiss, LA & Weiss, S 1998, 'Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction', Journal of Allergy and Clinical Immunology, vol. 102, no. 6 I, pp. 935-942. https://doi.org/10.1016/S0091-6749(98)70331-8
Nathan, R. A. ; Bernstein, J. A. ; Bielory, L. ; Bonuccelli, C. M. ; Calhoun, William ; Galant, S. P. ; Hanby, L. A. ; Kemp, J. P. ; Kylstra, J. W. ; Nayak, A. S. ; O'Connor, J. P. ; Schwartz, H. J. ; Southern, D. L. ; Spector, S. L. ; Williams, P. V. ; Aaronson, D. W. ; Albery, R. V. ; Auerbach, D. ; Bell, T. D. ; Berger, W. E. ; Bruce, C. A. ; Butterfield, J. H. ; Campbell, S. C. ; Chodosh, S. ; Chu, T. J. ; Cohen, M. ; Colton, J. A. ; DeGraff, A. C. ; Dockhorn, R. J. ; Edwards, T. B. ; Floreani, A. ; Gillman, S. A. ; Goldstein, S. ; Hampel, F. ; Hannaway, P. J. ; Hirsch, S. R. ; Kirby, L. ; Lang, D. M. ; Littlejohn, T. W. ; Mitchell, D. Q. ; Montanaro, T. ; Munk, Z. M. ; Pollard, S. ; Ratner, P. H. ; Rossoff, L. J. ; Rowe, M. S. ; Schatz, M. ; Taylor, J. R. ; Townley, R. G. ; Weiss, L. A. ; Weiss, S. / Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. In: Journal of Allergy and Clinical Immunology. 1998 ; Vol. 102, No. 6 I. pp. 935-942.
@article{be23b2c3f59c4026ac285c69d817a9ca,
title = "Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction",
abstract = "Background: Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma. Objectives: We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) during a 13- week, double-blind, placebo-controlled, multicenter trial in adults and adolescents with moderate reversible airflow obstruction. Methods: Patients (age range, 12 to 68 years) with total daytime asthma symptoms scores of 10 or greater over 7 consecutive days (maximum, 21/wk), FEV1 45{\%} or greater but less than or equal to 80{\%} of predicted value (≥6 hours after β2-agonist), and reversible airway disease were randomized to 20 mg zafirlukast twice daily (n(Z) = 231) or placebo twice daily (n(P) = 223). Efficacy was assessed from changes in daytime and nocturnal symptoms, β2-agonist use, nasal congestion score, and pulmonary function. QOL was evaluated with a disease- specific Asthma Quality of Life Questionnaire. Safety was determined from adverse event information and clinical laboratory test results. Results: Zafirlukast was significantly (P < .001) more effective than placebo, with reductions from baseline in the daytime asthma symptoms score (-23{\%}), nighttime awakenings with asthma (-19{\%}), and β2-agonist use (-24{\%}) and improvements from baseline in morning (+25 L/min) and evening (+18 L/min) peak expiratory flow rates. Compared with placebo, zafirlukast significantly (P ≤ .018) improved scores for QOL domains (activity limitations, symptoms, emotional function, and exposure to environmental stimuli) and overall QOL, with a significantly greater proportion of zafirlukast-treated patients demonstrating clinically meaningful improvements (≥0.5-unit change from baseline; P ≤ .037). The safety profile of zafirlukast was clinically indistinguishable from that of placebo. Conclusions: Zafirlukast is effective and well tolerated and improves QOL in the long-term treatment of patients with moderate reversible airflow obstruction.",
keywords = "Asthma, Leukotriene receptor antagonist, Nasal congestion, Number needed to treat, Peripheral blood eosinophils, Pulmonary function, Quality of life, Reversible airflow obstruction, Zafirlukast",
author = "Nathan, {R. A.} and Bernstein, {J. A.} and L. Bielory and Bonuccelli, {C. M.} and William Calhoun and Galant, {S. P.} and Hanby, {L. A.} and Kemp, {J. P.} and Kylstra, {J. W.} and Nayak, {A. S.} and O'Connor, {J. P.} and Schwartz, {H. J.} and Southern, {D. L.} and Spector, {S. L.} and Williams, {P. V.} and Aaronson, {D. W.} and Albery, {R. V.} and D. Auerbach and Bell, {T. D.} and Berger, {W. E.} and Bruce, {C. A.} and Butterfield, {J. H.} and Campbell, {S. C.} and S. Chodosh and Chu, {T. J.} and M. Cohen and Colton, {J. A.} and DeGraff, {A. C.} and Dockhorn, {R. J.} and Edwards, {T. B.} and A. Floreani and Gillman, {S. A.} and S. Goldstein and F. Hampel and Hannaway, {P. J.} and Hirsch, {S. R.} and L. Kirby and Lang, {D. M.} and Littlejohn, {T. W.} and Mitchell, {D. Q.} and T. Montanaro and Munk, {Z. M.} and S. Pollard and Ratner, {P. H.} and Rossoff, {L. J.} and Rowe, {M. S.} and M. Schatz and Taylor, {J. R.} and Townley, {R. G.} and Weiss, {L. A.} and S. Weiss",
year = "1998",
doi = "10.1016/S0091-6749(98)70331-8",
language = "English (US)",
volume = "102",
pages = "935--942",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6 I",

}

TY - JOUR

T1 - Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction

AU - Nathan, R. A.

AU - Bernstein, J. A.

AU - Bielory, L.

AU - Bonuccelli, C. M.

AU - Calhoun, William

AU - Galant, S. P.

AU - Hanby, L. A.

AU - Kemp, J. P.

AU - Kylstra, J. W.

AU - Nayak, A. S.

AU - O'Connor, J. P.

AU - Schwartz, H. J.

AU - Southern, D. L.

AU - Spector, S. L.

AU - Williams, P. V.

AU - Aaronson, D. W.

AU - Albery, R. V.

AU - Auerbach, D.

AU - Bell, T. D.

AU - Berger, W. E.

AU - Bruce, C. A.

AU - Butterfield, J. H.

AU - Campbell, S. C.

AU - Chodosh, S.

AU - Chu, T. J.

AU - Cohen, M.

AU - Colton, J. A.

AU - DeGraff, A. C.

AU - Dockhorn, R. J.

AU - Edwards, T. B.

AU - Floreani, A.

AU - Gillman, S. A.

AU - Goldstein, S.

AU - Hampel, F.

AU - Hannaway, P. J.

AU - Hirsch, S. R.

AU - Kirby, L.

AU - Lang, D. M.

AU - Littlejohn, T. W.

AU - Mitchell, D. Q.

AU - Montanaro, T.

AU - Munk, Z. M.

AU - Pollard, S.

AU - Ratner, P. H.

AU - Rossoff, L. J.

AU - Rowe, M. S.

AU - Schatz, M.

AU - Taylor, J. R.

AU - Townley, R. G.

AU - Weiss, L. A.

AU - Weiss, S.

PY - 1998

Y1 - 1998

N2 - Background: Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma. Objectives: We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) during a 13- week, double-blind, placebo-controlled, multicenter trial in adults and adolescents with moderate reversible airflow obstruction. Methods: Patients (age range, 12 to 68 years) with total daytime asthma symptoms scores of 10 or greater over 7 consecutive days (maximum, 21/wk), FEV1 45% or greater but less than or equal to 80% of predicted value (≥6 hours after β2-agonist), and reversible airway disease were randomized to 20 mg zafirlukast twice daily (n(Z) = 231) or placebo twice daily (n(P) = 223). Efficacy was assessed from changes in daytime and nocturnal symptoms, β2-agonist use, nasal congestion score, and pulmonary function. QOL was evaluated with a disease- specific Asthma Quality of Life Questionnaire. Safety was determined from adverse event information and clinical laboratory test results. Results: Zafirlukast was significantly (P < .001) more effective than placebo, with reductions from baseline in the daytime asthma symptoms score (-23%), nighttime awakenings with asthma (-19%), and β2-agonist use (-24%) and improvements from baseline in morning (+25 L/min) and evening (+18 L/min) peak expiratory flow rates. Compared with placebo, zafirlukast significantly (P ≤ .018) improved scores for QOL domains (activity limitations, symptoms, emotional function, and exposure to environmental stimuli) and overall QOL, with a significantly greater proportion of zafirlukast-treated patients demonstrating clinically meaningful improvements (≥0.5-unit change from baseline; P ≤ .037). The safety profile of zafirlukast was clinically indistinguishable from that of placebo. Conclusions: Zafirlukast is effective and well tolerated and improves QOL in the long-term treatment of patients with moderate reversible airflow obstruction.

AB - Background: Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma. Objectives: We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) during a 13- week, double-blind, placebo-controlled, multicenter trial in adults and adolescents with moderate reversible airflow obstruction. Methods: Patients (age range, 12 to 68 years) with total daytime asthma symptoms scores of 10 or greater over 7 consecutive days (maximum, 21/wk), FEV1 45% or greater but less than or equal to 80% of predicted value (≥6 hours after β2-agonist), and reversible airway disease were randomized to 20 mg zafirlukast twice daily (n(Z) = 231) or placebo twice daily (n(P) = 223). Efficacy was assessed from changes in daytime and nocturnal symptoms, β2-agonist use, nasal congestion score, and pulmonary function. QOL was evaluated with a disease- specific Asthma Quality of Life Questionnaire. Safety was determined from adverse event information and clinical laboratory test results. Results: Zafirlukast was significantly (P < .001) more effective than placebo, with reductions from baseline in the daytime asthma symptoms score (-23%), nighttime awakenings with asthma (-19%), and β2-agonist use (-24%) and improvements from baseline in morning (+25 L/min) and evening (+18 L/min) peak expiratory flow rates. Compared with placebo, zafirlukast significantly (P ≤ .018) improved scores for QOL domains (activity limitations, symptoms, emotional function, and exposure to environmental stimuli) and overall QOL, with a significantly greater proportion of zafirlukast-treated patients demonstrating clinically meaningful improvements (≥0.5-unit change from baseline; P ≤ .037). The safety profile of zafirlukast was clinically indistinguishable from that of placebo. Conclusions: Zafirlukast is effective and well tolerated and improves QOL in the long-term treatment of patients with moderate reversible airflow obstruction.

KW - Asthma

KW - Leukotriene receptor antagonist

KW - Nasal congestion

KW - Number needed to treat

KW - Peripheral blood eosinophils

KW - Pulmonary function

KW - Quality of life

KW - Reversible airflow obstruction

KW - Zafirlukast

UR - http://www.scopus.com/inward/record.url?scp=0032430610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032430610&partnerID=8YFLogxK

U2 - 10.1016/S0091-6749(98)70331-8

DO - 10.1016/S0091-6749(98)70331-8

M3 - Article

VL - 102

SP - 935

EP - 942

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6 I

ER -